The Edit. 11.10.2025.
Forging the Future of Finance.
Week of November 10th, 2025
Market Update
The Nasdaq Composite slid about 3% for the week as tech and AI-related stocks came under pressure.
Why it matters: Tech and growth stocks fell sharply, signalling a shift from high-valuation sectors and caution for investors heavy in AI and growth names.
HSBC offered about USD 13.6 billion to acquire the remaining stake in Hang Seng Bank and take the lender private.
Why it matters: The deal strengthens HSBC’s control in Hong Kong and signals renewed consolidation among major banks, potentially sparking re-ratings or merger expectations across the sector.
The U.S. federal government remains shut, delaying the release of key economic reports and hampering clarity for markets.
Why it matters: The ongoing government shutdown delays key economic reports that guide market expectations, creating uncertainty over growth, policy, and earnings. This uncertainty weighs on investor confidence, dampens spending and business activity, and drives a shift toward safer assets like Treasuries and gold.
Deal of the Week
Winner of Weight Loss Drug Battle Prevails
Pfizer Acquires Weight Loss Startup Metsera in $10 Billion Deal
On November 8, 2025, Pfizer (NYSE: PFE) clinched a deal to acquire Metsera (NASDAQ: MTSR), a clinical-stage obesity drug developer. The deal closed at a USD $10 billion figure after Metsera’s board accepted Pfizer’s sweetened offer of $86.25 per share. This barely topped a rival bid from Danish pharma company Novo Nordisk, and represents about a 3.7% premium to Metsera’s last closing price after a 60% stock surge during the company’s auction.
By making a move for Metsera, Pfizer gains a much-needed foothold in the booming weight loss drug market, which has been dominated by Novo and Eli Lilly after Pfizer’s own attempts to develop such a drug had failed. Metsera’s offerings are still years from approval, but analysts project they could exceed USD $5 billion in peak sales if successful.
The auction which prevailed for Metsera underscores a common trend in the pharmaceutical space of firms on the hunt for the next blockbuster obesity cure. Pfizer expects to close the merger swiftly after Metsera’s shareholder vote on Nov. 13, 2025, bringing Metsera’s scientists and promising weight loss experts to the company.
Why This Acquisition Matters
Pressure To Perform
The bidding war over Metsera featured multiple offer hikes and even lawsuits, a rare saga for a biotech deal. Pfizer ultimately had to commit USD $10 billion in its 7th bid, illustrating how intense competition and strategic necessity drove the price to new highs in the market. The steep price tag signals both confidence in Metsera’s technology and also raises pressure on Pfizer to deliver results.
Heavy Bet On Weight Loss
Weight loss medications are the hottest prize in pharma. Pfizer’s move shows it is determined not to be left behind in the USD $50+ Billion obesity drug market. Buying Metsera gives Pfizer a shot at its own drug in this high growth area whilst staying competitive amongst other companies in the industry.
Patriotic Edge
Pfizer’s winning bid was aided by an unusual factor. Through U.S. antitrust intervention, Trump’s Federal Trade Commission implicitly tipped the scales in Pfizer’s favour by scrutinizing Novo’s bid structure and ultimately prompting Metsera’s board to deem Novo’s offer too risky despite a higher headline price. Ultimately, U.S. regulators’ stance helped keep the promising obesity treatment in American hands, and signal towards an America first movement by Trump’s Federal Trade Commission.
Portfolio Refresh
For Pfizer, acquiring Metsera is a strategic pipeline refresh. It fills a critical gap in Pfizer’s portfolio as older drugs lose patent protection. Pfizer can immediately plug Metsera’s drug candidates into its extensive clinical development and marketing initiatives. By beating Novo, Pfizer prevents a rival from monopolizing another obesity drug, allowing for potentially friendlier regulatory reception for Pfizer’s own portfolio.
Interview Prep Questions
Associate - Investment Banking
Question: A private equity client is acquiring a company using 5x Debt/EBITDA. How would you analyze the company's "debt capacity," and what is the key difference between a maintenance covenant and an incurrence covenant in the credit agreement?
You’re being tested on:
LBO Mechanics, Credit Analysis, and Covenant Structures.
Core concept:
Debt capacity is not just a multiple; it's the ability to service debt (interest and principal) based on the company's projected free cash flow (FCF), particularly its resilience in a downside scenario.
Analysis involves building a debt schedule and running downside scenarios (e.g., revenue decline, margin compression) to see if FCF remains sufficient to cover mandatory payments.
Maintenance covenants (common in bank loans) require the borrower to maintain a certain credit ratio (e.g., Debt/EBITDA < 6x) at all times (tested quarterly). In contrast, incurrence covenants (common in high-yield bonds) only restrict future actions (e.g., issuing more debt) if a ratio is breached.
Common pitfalls.
Only using industry-average multiples to determine debt capacity without running a detailed, bottom-up FCF and covenant stress test.
Confusing GAAP Net Income with the Free Cash Flow actually available for debt service, thereby ignoring non-cash charges and working capital needs.
Assuming all debt is the same, and not differentiating between the flexibility of "cov-lite" incurrence-based debt and the strictness of maintenance-based bank debt.
Associate - M&A Deal Advisory
Question: You are performing due diligence on a software company. How do you assess the quality of its Annual Recurring Revenue (ARR), and what adjustments might you make to management's "Booked ARR" to arrive at "Net Recurring Revenue" for a QoE?
You’re being tested on:
SaaS Metrics, Revenue Recognition, and Quality of Revenue Analysis.
Core concept:
High-quality ARR is characterized by long-term, non-cancellable contracts, high net retention (low churn + high upsell), and a diversified customer base.
The QoE analysis must go beyond GAAP revenue to scrutinize the components of ARR. This involves testing customer contracts to isolate true recurring revenue from one-time fees (e.g., setup, implementation, consulting) that management may have included.
Adjustments include removing non-recurring items (one-time fees), normalizing for known churn that has occurred post-period end, and assessing the "at-risk" revenue from contracts up for renewal in the near term.
Common pitfalls.
Taking management's "Booked ARR" (which often includes new sales, even if not fully implemented) at face value without validating the underlying contracts.
Ignoring customer concentration or high gross churn, even if net retention looks healthy due to a few large upsells.
Failing to identify non-standard or "friendly" payment terms (e.g., extended receivables) that may inflate ARR but pose a high cash collection risk.
Analyst - Sales & Trading
Question: Explain the concept of "convexity" in a U.S. Treasury bond. If you are long a 10-year bond and short a 30-year bond in a duration-neutral 'flattener' trade, are you long or short convexity, and what does that mean for your P&L?
You’re being tested on:
Fixed Income Risk, Duration/Convexity Relationship, and Curve Trade Mechanics.
Core concept:
Duration measures the bond's sensitivity to a 1% parallel shift in interest rates. Convexity measures the rate of change of duration and describes the curvature of the price-yield relationship.
A bond with positive convexity (like a standard Treasury) will gain more from a rate cut than it loses from an equal-sized rate hike. This is a favourable attribute, and bonds with higher convexity are more expensive, all else equal.
In a duration-neutral trade, you are long the convexity of the 10-year bond and short the convexity of the 30-year bond. Since longer-dated bonds have much more convexity, this trade is net short convexity, meaning you will lose money from large, volatile rate moves in either direction, even if the curve doesn't change.
Common pitfalls
Believing that a "duration-neutral" trade has no risk, it is still exposed to non-parallel shifts (curve risk) and convexity (volatility risk).
Confusing positive convexity (good for a bondholder) with being "long" or "short" convexity in a relative-value trade (which describes your net portfolio exposure).
Ignoring the carry of the trade (the P&L bleed from the difference in yields) and focusing only on the price action.
